This ruling keeps Kroger's antitrust claims alive but is early-stage procedural. Monitor for summary judgment motions and potential settlement developments in the MDL. The case remains in discovery phase, no immediate financial impact on Kroger.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 3 $67.82entry
- T+1 · 9mo ago −0.95%α −1.65% · $67.17
- T+5 · 8mo ago +5.24%α +5.71% · $71.37
- T+20 · 8mo ago +5.42%α +9.57% · $71.49
- T+60 · 6mo ago −6.77%α −17.99% · $63.23
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
In the Generic Pharmaceuticals MDL 2724 antitrust litigation, the court denied Epic Pharma's motions to dismiss claims against it in eight of eleven complaints, including the one filed by The Kroger Co. The Kroger complaint survived because it sufficiently alleged Epic conspired with Lannett and Actavis to fix prices of Ursodiol, including a 1000% price increase by Epic. This ruling keeps Kroger's antitrust claims alive, preserving the potential for damages recovery, but is an interlocutory procedural ruling, not a final judgment, so no damages have been awarded.
Court Ruling Details
Key Facts
- Kroger is one of 11 plaintiffs in the Generic Pharmaceuticals MDL 2724 antitrust litigation against Epic Pharma.
- The court denied Epic's motion to dismiss Kroger's complaint, allowing the case to proceed.
- Kroger's complaint alleges Epic conspired with Lannett and Actavis to raise Ursodiol prices, including a 1000% price increase by Epic.
- Three other complaints (HCSC, Molina, CVS) were dismissed for failing to adequately plead Epic's involvement.
- This is a motion-to-dismiss ruling under Rule 12(b)(6), not a final judgment on the merits.
- No damages have been awarded; the ruling only determines the complaint states a plausible claim.
Financial Impact
No damages awarded or quantified in the ruling. Potential exposure for Epic is not stated.
Risk Factors
- Kroger must still prove its allegations at trial or through summary judgment.
- Appeals or further motions could still result in dismissal.
- The MDL has been ongoing for nearly a decade, resolution timeline is uncertain.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-lvpf066w-KR |
Track record
26 reports on KR
4 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +18.96% at T+60 after the May 19, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 4/10 Entry price pending
- Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $65.02 Now $70.67 +8.69% settles Nov 25
- Oct 23, 202624d ago Institutional Cluster Neutral 3/10 Entry $66.77 Now $70.67 +5.84% settles Nov 20
- Oct 20, 202627d ago 8-K Neutral 5/10 Entry $62.98 Now $70.67 +12.21% settles Nov 17
- Oct 5, 20266w ago 8-K Neutral 3/10 Entry $58.78 to $66.76 Now $70.67 +20.23% ▲ +13.58% +16.04% vs SPY
- Sep 30, 20266w ago Court Ruling Neutral 3/10 Entry $59.48 to $65.93 Now $70.67 +18.81% ▲ +10.84% +10.14% vs SPY
- Sep 28, 20267w ago 424B5 Neutral 3/10 Entry $59.69 to $66.77 Now $70.67 +18.40% ▲ +11.86% +11.89% vs SPY
- Sep 25, 20267w ago Press Release Neutral 2/10 Entry $58.74 to $66.77 Now $70.67 +20.31% ▲ +13.67% +15.15% vs SPY
- Sep 17, 20268w ago Press Release Neutral 2/10 Entry $60.00 to $63.63 Now $70.67 +17.78% ▲ +6.05% +5.85% vs SPY
- Sep 11, 20269w ago 8-K Mixed 5/10 Entry $58.49 to $61.64 Now $70.67 +20.82% ▲ +5.39% +3.52% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers